Soleo Health, an innovative leader and national provider of complex specialty pharmacy services, recently announced it was selected as a limited distribution partner for VYVGART
Idorsia Ltd. and Syneos Health® announced the extension of an existing collaboration to commercialize daridorexant, a novel dual orexin receptor antagonist for the treatment of insomnia across Europe and Canada
PANTHERx Rare was recently selected by Xeris Pharmaceuticals, Inc., a wholly owned subsidiary of Xeris Biopharma Holdings, Inc., as the exclusive U.S. pharmacy distribution partner for a new FDA-approved medication, Recorlev® (levoketoconazole).
ENTADFI will be marketed and distributed through Veru’s own telemedicine and telepharmacy services platform as well as through a partnership with GoodRx
Biologics by McKesson, selected as a specialty pharmacy distributor for three specialty drugs recently, is starting the new year with momentum
Amber Specialty Pharmacy announced that it will begin dispensing LIVTENCITY™ (maribavir), the first and only treatment indicated for the treatment of adults and pediatric patients (12 years of age and older and weighing at least 35 kg) with post-transplant CMV infection/disease
Aetna recently announced an initiative to launch a designated network to cover new gene therapies for rare diseases. This follows an initiative by CVS Health in 2019 to provide self-insured employers with a stop-loss program with Aetna health plans and cover gene therapies
AllianceRx Walgreens Prime (AllianceRx) is offering Arcalyst (rilonacept) and Gavreto (pralsetinib), two medicines prescribed for the treatment of specific kinds of cancer as well as an autoinflammatory cardiovascular disease